Immunotherapy for Gastrointestinal Malignancies
نویسندگان
چکیده
منابع مشابه
Immunotherapy for gastrointestinal malignancies.
BACKGROUND Gastrointestinal (GI) cancers are the most common human tumors encountered worldwide. The majority of GI cancers are unresectable at the time of diagnosis, and in the subset of patients undergoing resection, few are cured. There is only a modest improvement in survival with the addition of modalities such as chemotherapy and radiation therapy. Due to an increasing global cancer burde...
متن کاملImmunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies
Oncologic immunotherapy involves stimulating the immune system to more effectively identify and eradicate tumor cells that have successfully adapted to survive the body's natural immune defenses. Immunotherapy has shown great promise thus far by prolonging the lives of patients with a variety of malignancies, and has added a crucial new set of tools to the oncologists' armamentarium. The aim of...
متن کاملImmunotherapy of Genitourinary Malignancies
Most cancer patients are treated with some combination of surgery, radiation, and chemotherapy. Despite recent advances in local therapy with curative intent, chemotherapeutic treatments for metastatic disease often remain unsatisfying due to severe side effects and incomplete long-term remission. Therefore, the evaluation of novel therapeutic options is of great interest. Conventional, along w...
متن کاملImmunotherapy in genitourinary malignancies
Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic disease are treated with combination chemotherapies or targeted agents. These cytotoxic agents have good response rates and achieve palliation; however, complete responses are rarely seen. The field of cancer immunology has made rapid adva...
متن کاملChemotherapy of Gastrointestinal Malignancies.
Beginning with esophageal cancer of both the adeno and squamous variety, it would appear that combined modality therapy is here to stay. Most cancer programs now advocate chemotherapy, usually cisplatin and 5-fluorouracil together with radiation therapy, prior to definitive esophagectomy for localized disease. An exciting advance is the discovery of the activity of paclitaxel in this setting, a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Control
سال: 2013
ISSN: 1073-2748,1073-2748
DOI: 10.1177/107327481302000106